Cite
Subcutaneous Epcoritamab in Patients With Relapsed or Refractory Large B-Cell Lymphoma (EPCORE NHL-1): Pivotal Results From a Phase 2 Study.
MLA
Jurczak, Wojciech, et al. “Subcutaneous Epcoritamab in Patients With Relapsed or Refractory Large B-Cell Lymphoma (EPCORE NHL-1): Pivotal Results From a Phase 2 Study.” Acta Haematologica Polonica, vol. 53, no. A, July 2022, pp. 44–45. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=159129100&authtype=sso&custid=ns315887.
APA
Jurczak, W., Thieblemont, C., Phillips, T., Ghesquieres, H., Cheah, C. Y., Roost, M., Cunningham, D., Young Rok Do, Feldman, T., Gasiorowski, R., Tae Min Kim, Lewis, D. J., Van der Poel, M., Limei Poon, M., Doerr, T., Kilavuz, N., Menghui Chen, Sacchi, M., Elliott, B., & Hutchings, M. (2022). Subcutaneous Epcoritamab in Patients With Relapsed or Refractory Large B-Cell Lymphoma (EPCORE NHL-1): Pivotal Results From a Phase 2 Study. Acta Haematologica Polonica, 53(A), 44–45.
Chicago
Jurczak, Wojciech, Catherine Thieblemont, Tycel Phillips, Herve Ghesquieres, Chan Y. Cheah, Michael Roost, David Cunningham, et al. 2022. “Subcutaneous Epcoritamab in Patients With Relapsed or Refractory Large B-Cell Lymphoma (EPCORE NHL-1): Pivotal Results From a Phase 2 Study.” Acta Haematologica Polonica 53 (A): 44–45. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=159129100&authtype=sso&custid=ns315887.